Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 18 Colonic Neoplasms 4 Rectal Neoplasms 2 Neoplasm Metastasis 2 Stomach Neoplasms 1 Solid Tumor Cancer 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Metastatic Gastric Adenocarcinoma 1 HER2 IHC3+ Advanced Colorectal Cancer 1 Gastric and Gastroesophageal Junction Adenocarcinoma 1 Carcinoma 1 Advanced/Metastatic Solid Tumors 1 Advanced Gastric Cancer 1 Adenocarcinoma 1

Interventions

Oxaliplatin 64 pembrolizumab 48 Fluorouracil 44 Capecitabine 38 Nivolumab 33 Leucovorin 32 Paclitaxel 28 Trastuzumab 19 Docetaxel 18 Cisplatin 18 S 1 (combination) 16 Bevacizumab 15 Ramucirumab 13 Irinotecan 13 Drug Therapy 13 tislelizumab 12 Cyclophosphamide 12 fludarabine 10 Carboplatin 10 Radiotherapy 9 Magnetic Resonance Spectroscopy 9 trastuzumab deruxtecan 8 sintilimab 8 Specimen Handling 8 Biopsy 8 atezolizumab 7 Surgical Procedures, Operative 7 Gemcitabine 7 zolbetuximab 6 durvalumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Stomach Neoplasms × Trifluridine × 1 year × Clear all

NCT07212933 2025-10-08

RAK in GC

Chinese PLA General Hospital

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡